Hypertension in chronic kidney disease (CKD) patients is a risk factor for end-stage renal
disease, cardiovascular events, and mortality. Thus, the prevention and appropriate …

Diabetes drives an increasing burden of cardiovascular and renal disease worldwide,
motivating the search for new hypoglycemic agents that confer cardiac and renal protective …

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to improve
cardiovascular and renal outcomes in patients with established cardiovascular disease …

Introduction Hypertension is a well-established risk factor for cardiovascular (CV) events in
patients with chronic kidney disease (CKD), heart failure, obesity, and diabetes. Despite the …

Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium–
glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce …

Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …

Diabetic kidney disease (DKD) is a prevalent renal complication of diabetes mellitus that
ultimately develops into end-stage kidney disease (ESKD) when not managed …

Chronic kidney disease (CKD) is a major public health problem, increasing the risk of
cardiovascular events and death and potentially leading to kidney failure. Novel drugs that …

Purpose of Review Chronic kidney disease and end-stage kidney disease (ESKD) are well-
established risk factors for cardiovascular disease (CVD), the leading cause of mortality in …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been incorporated as guideline-
directed medical therapy for heart failure with reduced ejection fraction. Recent trials clearly …